●    Revenue up 4.9%, enabling market share gains despite difficulties in 2023

●    2023 operating profitability¹ at an all-time high of 23.2% of revenue
     ○ Up 0.4 points compared to 2022 

●    Strong momentum expected in 2024
     ○  Expected revenue growth of 4% to 6% at constant exchange rates and scope
     ○  Operating profitability¹ expected to rise by 0,5 point
 

On November 1, we successfully finalized the acquisition of a majority stake in Globion. This transaction will bolster our position of animal health leader in India by extending Virbac India’s existing poultry portfolio to the growing segment of avian vaccines. 

Revenue growth at the end of September at +2.8% at constant exchange rates and scope thanks to a strong activity rebound in the third quarter (+7.8% at constant exchange rates and scope).

Virbac announces the signing of an agreement to acquire Globion, a leading Indian poultry vaccines specialist. This transaction will bolster our position of animal health market leader in India by extending Virbac India’s existing poultry portfolio to the growing segment of avian vaccines.

Current operating income before R&D slightly improving throughout first half of 2023 in percentage of revenue

Following the decision of the board of directors on June 19, 2023 and its approval by the shareholder’s meeting, we are going to buy back 100,000 of our own shares (less than 1.25% of the capital). Main objective: to decrease the company's share capital by canceling treasury shares purchased.

At the end of August, with our priority systems fully restored and functional following the June cyberattack, we will be able to publish our mid-year results on September 28 with a two-week delay.

Revenue up about 2% during the second quarter and stable at the end of June despite two unfavorable one-off effects throughout the semester

Virbac reassesses its 2023 growth and Adjusted EBIT¹ forecast

Slight decline in first-quarter revenue primarily due to a base effect as well as a context of market slowdown